Voriaid 200 mg (Tablet)

Indications

• Treatment of invasive aspergillosis
• Treatment of candidemia in nonneutropenic patients
• Treatment of disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds
• Treatment of esophageal candidiasis
• Treatment of serious infections caused by Scedosporium apiospermum and Fusarium Species
• Treatment for patients intolerant of or refractory to other therapies

Pharmacology

• Voriconazole is a triazole antifungal medication
• Binds and inhibits ergosterol synthesis
• Inhibits CYP450-dependent 14-alpha sterol demethylase
• Results in depletion of ergosterol in fungal cell membrane

Dosage & Administration

• Oral administration
• Loading dose regimen for patients at or over 40 kg body weight
• Loading dose regimen for patients below 40 kg body weight
• Maintenance dose regimen
• Injection dosage for invasive aspergillosis
• Injection dosage for candidemia in nonneutropenic patients
• Injection dosage for Scedosporiosis and Fusariosis

Interaction

• Adjust Voriaid dosage with CYP3A4, CYP2C9, and CYP2C19 inhibitors or inducers
• Monitoring for adverse reactions or lack of efficacy with Voriaid interaction
• Increase maintenance dosage of Voriaid with co-administration of Phenytoin or Efavirenz
• Increase concentrations and activity of drugs that are CYP3A4, CYP2C9, and CYP2C19 substrates
• Reduce doses of drugs and monitor for adverse reactions

Contraindications

• Known hypersensitivity to Voriconazole or any other components
• Co-administration with terfenadine, astemizole, cisapride, pimozide, or quinidine
• Co-administration with rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John's Wort

Side Effects

• Abdominal pain
• Anemia
• Blurred vision
• Headache
• Chest pain
• Nausea
• Diarrhea

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• Use during pregnancy only if potential benefit justifies potential risk to fetus

Precautions & Warnings

• Careful assessment of benefit-risk balance for long term exposure greater than 180 days
• Squamous cell carcinoma of the skin (SCC) reported in relation with long-term Voriaid treatment

Use in Special Populations

• Efficacy not established in children under 12 years of age

Overdose Effects

• No data found about overdose of Voriaid

Therapeutic Class

• Other Antifungal preparations

Reconstitution

• Shake the bottle well before adding water to loosen the powder
• Add 25 ml of boiled and cooled water to the bottle
• Shake vigorously until powder is completely mixed with the water
• Store reconstituted suspension between 15°C-30°C
• Discard suspension 14 days after reconstitution

Storage Conditions

• Keep out of reach of children
• Store in a dry place, below 25°C temperature, and protected from light
• Store Voriaid powder for suspension between 2°C to 8°C temperature

Related Brands

• Voriaid 50 mg (Tablet) - labaid-pharma-ltd
• Vorier 200 mg (Tablet) - one-pharma-ltd
• Voriderm 200 mg/vial (IV Injection) - incepta-pharmaceuticals-ltd
• Vcand 200 mg/5 ml (Powder for Suspension) - biopharma-limited
• Vcand 50 mg (Tablet) - biopharma-limited